Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets.
Severe acute respiratory syndrome (SARS) caused by a newly identified coronavirus (SARS-CoV) is a serious emerging human infectious disease. In this report, we immunized ferrets (Mustela putorius furo) with recombinant modified vaccinia virus Ankara (rMVA) expressing the SARS-CoV spike (S) protein. Immunized ferrets developed a more rapid and vigorous neutralizing antibody response than control animals after challenge with SARS-CoV; however, they also exhibited strong inflammatory responses in liver tissue. Inflammation in control animals exposed to SARS-CoV was relatively mild. Thus, our data suggest that vaccination with rMVA expressing SARS-CoV S protein is associated with enhanced hepatitis.
Weingartl
Hana
H
National Centre for Foreign Animal Diseases, Canadian Science Centre for Human and Animal Health, 1015 Arlington St., Winnipeg, Manitoba, Canada R3E 3R2.
Czub
Markus
M
Czub
Stefanie
S
Neufeld
James
J
Marszal
Peter
P
Gren
Jason
J
Smith
Greg
G
Jones
Shane
S
Proulx
Roxanne
R
Deschambault
Yvonne
Y
Grudeski
Elsie
E
Andonov
Anton
A
He
Runtao
R
Li
Yan
Y
Copps
John
J
Grolla
Allen
A
Dick
Daryl
D
Berry
Jody
J
Ganske
Shelley
S
Manning
Lisa
L
Cao
Jingxin
J
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D005289:Ferrets; D006505:Hepatitis / Q000209:etiology*; D008099:Liver / Q000473:pathology; D008297:Male; D008562:Membrane Glycoproteins / Q000235:genetics / Q000276:immunology*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D045473:Severe acute respiratory syndrome-related coronavirus / Q000276:immunology*; D064370:Spike Glycoprotein, Coronavirus; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000009:adverse effects*; D014616:Vaccinia virus / Q000276:immunology*; D014759:Viral Envelope Proteins / Q000235:genetics / Q000276:immunology*; D014765:Viral Vaccines / Q000009:adverse effects*
D000914:Antibodies, Viral; D008562:Membrane Glycoproteins; D064370:Spike Glycoprotein, Coronavirus; D014614:Vaccines, Synthetic; D014759:Viral Envelope Proteins; D014765:Viral Vaccines; C578557:spike glycoprotein, SARS-CoV; C578553:spike protein, mouse hepatitis virus